The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Collaborators:
City of Hope National Medical Center
Fordham University
Columbia University
New York University School of Medicine
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00579072
First received: December 19, 2007
Last updated: April 21, 2014
Last verified: April 2014

December 19, 2007
April 21, 2014
August 2006
December 2015   (final data collection date for primary outcome measure)
Describe changes in cognitive functioning over 6 mos in 70 men with prostate cancer who are about to start androgen ablation therapy vs 70 men with prostate cancer with NED & no medical indication to start Comparison androgen ablation therapy [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Describe changes in cognitive functioning over 6 mo in 40 men w prostate cancer who are about to start androgen ablation therapy vs. 40 men w prostate cancer with no evidence of disease and no medical indication to start androgen ablation therapy. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00579072 on ClinicalTrials.gov Archive Site
  • Describe differences in cognitive functioning in 80 men with prostate cancer who received Comparison androgen ablation therapy for 6 months - 3 years vs.140 men with prostate cancer who are hormone naïve. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • To describe the differences in cognitive functioning in 70 men with prostate cancer who have received androgen ablation therapy for 6 months vs. 80 men with prostate cancer who have received Comparison androgen ablation therapy for 6 months-3 years. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Describe differences in cognitive functioning in 80 men w prostate cancer who received androgen ablation therapy for 2-3 years vs. 80 men w prostate cancer who are hormone naïve. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

The purpose of this study is to find out if therapy with hormones (such as Lupron, Casodex, Zolodex or Degarelix) change a person's thinking abilities.

To find out if this treatment changes things like memory, learning, or concentration. This study is being done to learn more about the effects of this treatment and to help men in the future who use the hormones Lupron, Casodex, Zolodex or Degarelix.

If you choose to take part, you will be asked to do the following:

Fill out questionnaires that ask about:

  • Your age, eduction, race, and income
  • Depression
  • Stress
  • Energy level
  • Pain
  • Memory
  • Ability to perform daily tasks such as eating, dressing, and taking a shower

Research staff will evaluate you on the following:

  • Memory
  • How you prefer to learn new information
  • Copying designs such as rectangles, squares, and circles
  • How quickly you think
  • Your attention span
  • How well you plan and organize shapes and colors into specific categories
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Prostate Cancer Patients

Prostate Cancer
  • Behavioral: Questionaires
    We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 140 men with prostate cancer. All 140 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 140 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 70 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).
  • Behavioral: Questionaires
    To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 80 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 80 men in the 2-Year Androgen Ablation Group to the 140 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
  • Longitudinal Study
    Take part in this study because subject has prostate cancer and are over 64 years old. To run this study,need men from two groups. First, we need men who are about to start hormone treatment. Second, we need men who do not plan to use this treatment in the future. We will use this second group as a control group and compare this group to the men who are using this treatment.
    Intervention: Behavioral: Questionaires
  • Group Comparison
    Take part in this study because subject has prostate cancer and are over 64 years old. Also, because subject has been on hormone therapy for about two to three years.
    Intervention: Behavioral: Questionaires
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
220
December 2015
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria is the same at both sites, and is outlined below:

Inclusion Criteria:

Comparison Androgen Ablation Group

  1. Diagnosis of prostate cancer
  2. Age 65 or older
  3. Ability to converse, write and read English
  4. Able to provide informed consent
  5. Have been on continuous androgen ablation therapy for 6 months to-3 years

Androgen Ablation Subgroup

  1. Diagnosis of prostate cancer
  2. Age 65 or older
  3. Ability to converse, write and read English
  4. Able to provide informed consent
  5. Starting androgen ablation therapy
  6. No androgen ablation therapy within the past year

No Androgen Ablation Subgroup

  1. Diagnosis of prostate cancer
  2. Age 65 or older
  3. At least 1-year post definitive localized treatment
  4. Ability to converse, write and read English
  5. Able to provide informed consent
  6. Not anticipated to start androgen ablation therapy

Exclusion Criteria:

All Groups

2) Previous or current treatment with chemotherapy 3) History of neurological brain damage 4) History of untreated psychiatric disease 5) Previous head traumas 6) Current use of opioids 7) History of developmental disorders 8) Current history of alcohol or substance abuse

Androgen Ablation Subgroup and No Androgen Ablation Subgroup Only

1) History of androgen ablation therapy within the past year of the date of consent

Male
65 Years and older
No
Contact: Christian Nelson, PhD 646-888-0030
United States
 
NCT00579072
06-084, R03 CA119756-01
No
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
  • National Cancer Institute (NCI)
  • City of Hope National Medical Center
  • Fordham University
  • Columbia University
  • New York University School of Medicine
Principal Investigator: Christian Nelson, PhD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP